Groundbreaking clinical validation of icobrain aria

In a landmark achievement for Alzheimer's disease treatment, icometrix unveils the groundbreaking clinical validation of icobrain aria in JAMA Open Network, setting a new precedent in the safety monitoring of patients undergoing amyloid beta-directed antibody therapy. 

The detection and quantification of amyloid-related imaging abnormalities (ARIA) informs treatment continuation and dosing decisions for the newly available disease-modifying treatments for Alzheimer’s disease. In this paper, we demonstrate that radiological reading performance significantly improves with the assistance of icobrain aria, as evident through a reader study including 16 radiologists and 199 pairs of brain MRI scans from AD patients receiving amyloid beta-directed antibody therapy.

By the assistance of icobrain aria, radiologists were significantly better in detecting ARIA as compared to unassisted radiologists, both for ARIA-E as well as ARIA-H. Moreover, comparing unassisted versus assisted reads, sensitivity of detecting increased from 71% to 87% for ARIA-E detection and from 69% to 79% ARIA-H. This means that by the use of icobrain aria, less ARIA findings were missed.

We are beyond proud to show you this exciting outcome of our dedicated work, which will be pivotal with disease-modifying treatments for AD slowly paving their way to clinical practice and worldwide adoption. With icobrain aria (FDA approval pending), icometrix is your ideal partner to improve the safety monitoring and management of AD patients treated with amyloid beta-directed monoclonal antibody therapies.

Want to learn more? Read all about it in the full paper or contact us directly.